Teva Pharmaceutical Industries (NYSE:TEVA) Sees 14% Stock Price Rise With FDA Acceptance Of New Drug Application

Teva Pharmaceutical Industries (NYSE:TEVA) saw its stock price move up 14% over the last week, a notable jump attributed partially to recent regulatory milestones. The U.S. FDA's acceptance of a Supplemental New Drug Application for UZEDY, an extended-release injectable for maintenance treatment of bipolar I disorder, highlights Teva’s ongoing efforts in drug development. Additionally, the company's pursuit of biosimilars like AVT06, targeting eye disorders, underscores its strategic focus on expanding its therapeutic portfolio. Meanwhile, broader market trends show a mixed picture, with the Dow Jones, S&P 500, and Nasdaq all experiencing declines, counteracting some recent gains. Economic concerns such as recession potential and tariff impacts continue to weigh on investor sentiment. Despite this volatile market backdrop, Teva's advancements appear to be driving optimism among investors, distinguishing it from the broader downturn affecting major indexes and tech stocks.

Examine Teva Pharmaceutical Industries' earnings growth report to understand how analysts expect it to perform.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 19 best rare earth metal stocks of the very few that mine this essential strategic resource.

Over the last five years, Teva Pharmaceutical Industries has achieved a total return of 123.10%, supported by a series of pivotal developments. In 2023, Teva resolved significant legal challenges, including a deferred prosecution agreement related to price-fixing charges, with a US$225 million fine, and a settlement with the Israel Tax Authority for US$750 million. These actions, although costly, eliminated potential uncertainties and enabled the company to refocus on its core businesses.

Additionally, collaborations have proven influential, with an agreement in 2023 with Alvotech for the U.S. commercialization of five biosimilar candidates. This partnership aids Teva's expansion in a competitive pharmaceutical landscape. The acceptance of the Biologics License Application for AVT06 in early 2025 also underscores its progress in diversifying its product offerings. Moreover, with the resolution of legal obligations and strategic product launches, Teva exceeded both U.S. Pharmaceuticals industry and broader market returns over the past year.

Hold shares in Teva Pharmaceutical Industries? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com